Immune Monitor - July 2024

By SITC Communications posted 07-25-2024 15:25

  

A Message from the President

Last month, SITC launched a three-year strategic plan highlighting “global access and impact” as one of the six main strategic goals. This goal aims to collaborate strategically to expand the global reach of SITC resources and increase immuno-oncology access to diverse populations worldwide. 
A big part of this is elevating a rich oncology community through SITC’s diversity, equity, and inclusion (DEI) strategic plan. DEI isn’t a single initiative or program at SITC, it is a core value that is integrated into everything SITC does, led by a committee of dedicated volunteers. Most recently, the DEI committee organized a new listening session focused on women in science and medicine. Female SITC leaders share their experiences in their scientific and medical research careers to highlight unique challenges women professionals overcome in the IO field, and to promote diversity in clinical and biomedical research. To view past listening sessions, click here.
Also supporting women in IO is the annual Women in Cancer Immunotherapy Network (WIN) Leadership Institute. Championed by Lisa H. Butterfield, PhD, the first female SITC president, the WIN Leadership Institute assembles women working throughout the cancer immunotherapy field for two days of professional development and networking. If you’d like to be notified about the 2025 WIN Leadership Institute, simply complete the information form on the WIN webpage.
To expand our global reach, SITC is implementing initiatives including the new webinar series, Increasing Access to IO: A Global Webinar Series. The Global Access and Impact Committee, in collaboration with the DEI Committee, launched this education program specifically for international audiences. The series’ objective is to discuss challenges facing international clinical teams when treating patients, providing education and awareness to the obstacles impeding equitable access to IO around the globe. To further expand our global reach, SITC now offers free membership and program accessibility for individuals living in low- and lower-middle income economies (LMIEs), an important step to broadening access to SITC’s education programming.
Weaving DEI through society initiatives and growing globally continue to be priorities for SITC. I am excited about the many ways we will move forward to create inclusive opportunities in cancer immunotherapy research and clinical care around the world. 

Leisha A. Emens, MD, PhD
SITC President

Program Spotlight
SITC Immuno-oncology Drug Development Summit
Building on the landmark approvals of the first immuno-oncology (IO) agents, this interactive summit – held Sept. 30–Oct. 1 in Boston, MA – will not just explore the pathway to FDA approval for current IO therapeutics, but also actively engage the community in discussions and challenges.
The two-day program will feature sessions on Investor Perspectives on Next Generation IO Drug Development, Artificial Intelligence in Drug Creation, Drug Development Strategies for Immune Cell Engagers and CARs and much more! Join us as we explore the landscape of state-of-the-art modern IO drug development.
0 comments
5 views

Related Content

Permalink

https://www.sitcancer.org/blogs/sitc-communications/2024/07/25/immune-monitor-july-2024